Literature DB >> 15602707

Barriers to adherence of deferoxamine usage in sickle cell disease.

Marsha J Treadwell1, Amy W Law, Jennifer Sung, Ekua Hackney-Stephens, Keith Quirolo, Eileen Murray, G Alastair Glendenning, Elliott Vichinsky.   

Abstract

BACKGROUND: We hypothesized that child cognitive disability would be a significant risk factor for non-adherence with home deferoxamine (DFO) administration and that a factor that would contribute to improved adherence would be sharing of responsibilities for chelation between parents and patients. We explored the influences on adherence of behavioral and psychological adjustment; family stress; perceived convenience of and satisfaction with the DFO regimen; and parent and patient knowledge about DFO. PROCEDURE: Fifteen pediatric patients with sickle cell disease (SCD) who had evidence of excessive iron stores, and their parents, were interviewed about adherence and responsibility for chelation therapy. A neuropsychological assessment battery was administered to the patients. Family stress, the child's emotional and behavioral status, knowledge about chelation and iron overload were explored. Adherence was rated objectively using pharmacy refill patterns and observable signs of chelation.
RESULTS: Sharing of responsibilities for chelation between parents and children was related to better adherence while neuropsychological status bore a complex relation to adherence. Of the exploratory variables, low family stress were related to better adherence while satisfaction with the home care regimen and convenience ratings were not useful in predicting adherence. No one element of adherence, even objective measures, was capable of classifying adherence, while a multifactorial scheme categorizing adherent, partially adherent and non-adherent groups demonstrated good face validity.
CONCLUSIONS: Supporting developmentally appropriate sharing of responsibilities for self-care is critical, taking patient neurocognitive status into consideration. Clinicians should evaluate adherence using a multifactorial model that highlights the most salient targets for intervention.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15602707     DOI: 10.1002/pbc.20290

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  15 in total

1.  Adherence to hydroxyurea therapy in children with sickle cell anemia.

Authors:  Courtney D Thornburg; Agustin Calatroni; Marilyn Telen; Alex R Kemper
Journal:  J Pediatr       Date:  2009-11-01       Impact factor: 4.406

2.  Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.

Authors:  Arlene Smaldone; Sally Findley; Suzanne Bakken; L Adriana Matiz; Susan L Rosenthal; Haomiao Jia; Sergio Matos; Deepa Manwani; Nancy S Green
Journal:  Contemp Clin Trials       Date:  2016-06-17       Impact factor: 2.226

Review 3.  Medication adherence among pediatric patients with sickle cell disease: a systematic review.

Authors:  Kathleen E Walsh; Sarah L Cutrona; Patricia L Kavanagh; Lori E Crosby; Chris Malone; Katie Lobner; David G Bundy
Journal:  Pediatrics       Date:  2014-11-17       Impact factor: 7.124

4.  Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload.

Authors:  Russell E Ware; William H Schultz; Nancy Yovetich; Nicole A Mortier; Ofelia Alvarez; Lee Hilliard; Rathi V Iyer; Scott T Miller; Zora R Rogers; J Paul Scott; Myron Waclawiw; Ronald W Helms
Journal:  Pediatr Blood Cancer       Date:  2011-08-08       Impact factor: 3.167

Review 5.  Optimal management strategies for chronic iron overload.

Authors:  James C Barton
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Systematic and Meta-Analytic Review: Medication Adherence Among Pediatric Patients With Sickle Cell Disease.

Authors:  Kristin Loiselle; Jennifer L Lee; Lauren Szulczewski; Sarah Drake; Lori E Crosby; Ahna L H Pai
Journal:  J Pediatr Psychol       Date:  2015-09-18

7.  Adherence to study medication and visits: data from the BABY HUG trial.

Authors:  Courtney D Thornburg; Zora R Rogers; Michael R Jeng; Sohail R Rana; Rathi V Iyer; Lane Faughnan; Leann Hassen; Jennifer Marshall; Roy P McDonald; Winfred C Wang; Xiangke Huang; Renée C Rees
Journal:  Pediatr Blood Cancer       Date:  2010-02       Impact factor: 3.167

8.  Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions.

Authors:  Ellen B Fung; Paul R Harmatz; Meredith Milet; Vinod Balasa; Samir K Ballas; James F Casella; Lee Hilliard; Abdullah Kutlar; Kenneth L McClain; Nancy F Olivieri; John B Porter; Elliott P Vichinsky
Journal:  Transfusion       Date:  2008-05-29       Impact factor: 3.157

9.  Integrating interactive web-based technology to assess adherence and clinical outcomes in pediatric sickle cell disease.

Authors:  Lori E Crosby; Ilana Barach; Meghan E McGrady; Karen A Kalinyak; Adryan R Eastin; Monica J Mitchell
Journal:  Anemia       Date:  2012-06-04

Review 10.  Chelation therapy for iron overload.

Authors:  James C Barton
Journal:  Curr Gastroenterol Rep       Date:  2007-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.